1 reply to this topic

[experimenting]

Stock is now 1/100th what it was just 4 years ago. And yet most people here seem to see NSI189 as a game changer (I did).

What gives?

[Turnbuckle]

The stock took a final nose dive in the middle of 2017 when this came out--

 

JULY 25, 2017

GERMANTOWN, Md., July 25, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced top-line results from its exploratory Phase 2 clinical trial examining the efficacy of NSI-189 at 40 mg once daily (QD) and 40 mg twice daily (BID) compared to placebo for the treatment of major depressive disorder (MDD).  The study, which utilized the two-staged sequential parallel comparison design (SPCD), did not meet its primary efficacy endpoint of a statistically significant reduction in depression symptoms on the Montgomery-Asberg Depression Rating Scale (MADRS).  However, the 40 mg QD dose was directionally positive on the MADRS.

https://www.neuralst...-of-nsi-189-for